Terms: = Endocrine gland cancer AND ERG, P11308, 2078 AND Treatment
11 results:
1. Primary ovarian angiosarcoma: a rare and recognizable ovarian tumor.
Ye H; Lin M; Li R; Qin S; Hou G; Chen H; Li X
J Ovarian Res; 2021 Jan; 14(1):21. PubMed ID: 33509230
[TBL] [Abstract] [Full Text] [Related]
2. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
[TBL] [Abstract] [Full Text] [Related]
3. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Abdulla A; Bagust A; Beale S; Richardson M; Stainthorpe A; Boland A; Kotas E; McEntee J; Palmer D
Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
[TBL] [Abstract] [Full Text] [Related]
4. Unilateral cancer-associated retinopathy: diagnosis, serology and treatment.
Roels D; Ueno S; Talianu CD; Draganova D; Kondo M; Leroy BP
Doc Ophthalmol; 2017 Dec; 135(3):233-240. PubMed ID: 28815346
[TBL] [Abstract] [Full Text] [Related]
5. Olaparib for Maintenance treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Harnan S; Ren S; Thokala P; Wong R; Mukuria C; Green C; Pledge S; Tidy J
Pharmacoeconomics; 2017 Jan; 35(1):97-109. PubMed ID: 27506954
[TBL] [Abstract] [Full Text] [Related]
6. Combined use of radioiodine therapy and radiofrequency ablation in treating postsurgical thyroid remnant of differentiated thyroid carcinoma.
Long B; Li L; Yao L; Chen S; Yi H; Ye X; Xu D; Wu P
J Cancer Res Ther; 2015 Nov; 11 Suppl():C244-7. PubMed ID: 26612446
[TBL] [Abstract] [Full Text] [Related]
7. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.
Klimstra DS; Beltran H; Lilenbaum R; Bergsland E
Am Soc Clin Oncol Educ Book; 2015; ():92-103. PubMed ID: 25993147
[TBL] [Abstract] [Full Text] [Related]
8. Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas.
Micci F; Panagopoulos I; Thorsen J; Davidson B; Tropé CG; Heim S
PLoS Biol; 2014 Feb; 12(2):e1001784. PubMed ID: 24504521
[TBL] [Abstract] [Full Text] [Related]
9. Trabectedin for the treatment of relapsed ovarian cancer.
Papaioannou D; Rafia R; Stevenson MD; Stevens JW; Evans P
Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655
[TBL] [Abstract] [Full Text] [Related]
10. [Borderline ovarian tumors and global radiation in relation with climate change impact].
Luchian AM; Pricop M
Rev Med Chir Soc Med Nat Iasi; 2011; 115(3):813-9. PubMed ID: 22046792
[TBL] [Abstract] [Full Text] [Related]
11. Effects of percutaneous laser ablation treatment in benign solitary thyroid nodules on nodule volume, thyroglobulin and anti-thyroglobulin levels, and cytopathology of nodule in 1 yr follow-up.
Cakir B; Topaloglu O; Gul K; Agac T; Aydin C; Dirikoc A; Gumus M; Yazicioglu K; Ersoy RU; Ugras S
J Endocrinol Invest; 2006 Nov; 29(10):876-84. PubMed ID: 17185895
[TBL] [Abstract] [Full Text] [Related]
